177Lu-NM600 Targeted Radionuclide Therapy Extends Survival in Syngeneic Murine Models of Triple-Negative Breast Cancer

Conclusion: Overall, our results suggest that 177Lu-NM600 targeted radionuclide therapy has potential for TNBC and merits further exploration in a clinical setting.

Source: Journal of Nuclear Medicine - August 2, 2020 Category: Nuclear Medicine Authors: Hernandez, R., Grudzinski, J. J., Aluicio-Sarduy, E., Massey, C. F., Pinchuk, A. N., Bitton, A. N., Patel, R., Zhang, R., Rao, A. V., Iyer, G., Engle, J. W., Weichert, J. P. Tags: Basic Source Type: research